Clinical and Imaging Findings in Childhood Posterior Reversible Encephalopathy Syndrome

How To Cite This Article: Gungor S, Kilic B, Tabel Y, Selimoglu A, Ozgen U, Yilmaz S, Sigirci A. Clinical and Imaging Findings in Childhood Posterior Reversible Encephalopathy Syndrome. Iran J Child Neurol. Winter 2018; 12(1):16-25.

Abstract

Objective

Posterior reversible encephalopathy syndrome (PRES) is characterized by typical radiologic findings in the posterior regions of the cerebral hemispheres and cerebellum. The symptoms include headache, nausea, vomiting, visual disturbances, focal neurologic deficits, and seizures. The aim of this study is to evaluate the clinical and radiological features of PRES in children and to emphasize the recognition of atypical features.

Materials & Methods

We retrospectively examined 23 children with PRES from Mar 2010-Apr 2015 in Inonu University Turgut Ozal Medical Center in Turkey. We compared the clinical features and cranial MRI findings between underlying diseases of PRES.

Results

The most common precipitating factors were hypertension (78.2%) and medications, namely immunosuppressive and antineoplastic agents (60.8%). Manifestations included mental changes (100%), seizures (95.6%), headache (60.8%), and visual disturbances (21.7%) of mean 3.6 (range 1-10) days’ duration. Cranial magnetic resonance imaging (MRI) showed bilateral occipital lesions in all patients, associated in 82.6% with less typical distribution of lesions in frontal, temporal or parietal lobes, cerebellum, corpus callosum, basal ganglia, thalamus, and brain stem. Frontal involvement was predominant, observed in 56.5% of patients. Clinical recovery was followed by radiologic resolution in all patients.

Conclusion

PRES is often unsuspected by the clinician, thus radiologists may be the first to suggest this diagnosis on an MRI obtained for seizures or encephalopathy. Atypical MRI finding is seen quite often. Rapid diagnosis and treatment are required to avoid a devastating outcome.

Keywords: Children; Posterior reversible encephalopathy syndrome; Seizure; Atypical radiological finding
Clinical and Imaging Findings in Childhood Posterior Reversible Encephalopathy Syndrome

Introduction
Posterior reversible encephalopathy syndrome (PRES) is a clinico-radiological syndrome defined in 1996. Clinically, it is characterized by headache, changes in mental status, seizures, and visual disturbances (1). In many cases, severe headache is associated with a sudden rise in blood pressure (2). Except for hypertensive encephalopathy, etiology of PRES includes preeclampsia (3,4), sepsis (4), acute glomerulonephritis (5,6), lupus nephritis (7), organ transplantation (8), peritoneal dialysis (9), usage of cyclosporine A (1), tacrolimus (10,11), intrathecal methotrexate, cytarabine, daunorubicin, vincristine, and L-asparaginase (12). Although hypertension is frequent, 20%-30% are normotensive (10, 13).

Pathogenesis is based on transient changes in the posterior circulation of the brain. Neuro-imaging is important for diagnosis. Computed tomography (CT) or magnetic resonance imaging (MRI) reveal diffuse edema more prominent in the parietal and occipital lobes bilaterally (4,14). Elimination of the underlying etiology and regulation of blood pressure are the first measures in PRES (8,13).

Patients diagnosed and treated rapidly may recover completely within a few weeks. Due to the lack of specific clinical symptoms of the syndrome, it can be confused with other clinical diagnoses which may lead to unnecessary or inappropriate treatments (4,14).

In this study, clinical and radiological findings of children diagnosed with PRES in our clinics were reviewed.

Materials and Methods
We retrospectively analyzed the data of 23 pediatric patients who received the diagnosis of PRES from Mar 2010-Apr 2015 in various units of Inonu University Turgut Ozal Medical Center in Turkey: organ and bone marrow transplantation unit, Pediatric Intensive Care, Pediatric subspecialty departments of Gastroenterology, Oncology, Nephrology, or Rheumatology. Criteria for inclusion were 1) symptoms and signs compatible with PRES such as seizures, headache, visual disturbances, and altered mental function on a background of underlying primary disease, and 2) supportive imaging findings. Demographic data, clinical findings, neurological signs, length of hospital stay, concurrent medical illnesses, recently used drugs, blood pressure values during the symptoms, and cranial MRI findings were recorded. Hypertension was defined as systolic and/or diastolic blood pressure values higher than the 95% percentile for age (15).

MRI studies were performed on 1.5 Tesla MRI devices (Magnetom; Siemens, Germany). T2-weighted axial and sagittal, fluid-attenuated inversion recovery (FLAIR) axial, T1-weighted axial contrast-enhanced and unenhanced images were taken. Diffusion-weighted images and values were used and ADC maps were obtained. Cranial MRI was performed on all patients within the first three days after the onset of neurological symptoms. At least one more brain MRI was made during the follow-up. Two neuroradiologists interpreted all images. Typical MRI findings were defined as hyperintensity in subcortical white matter on T2A and FLAIR images and increase in ADC values in the posterior parietal, occipital, and temporal areas. Atypical MRI findings were defined as frontal lobe, brain stem, and cerebellar involvements, cytotoxic edema, hemorrhage, and contrast enhancement.

This study was performed with approval from the Institutional Review Board of Inonu University Research Council.

Results
There were 23 children aged 1-16 (mean 7.8) yr, 13 boys, and 10 girls. Demographic and clinical data are summarized in Table 1. Among underlying primary diseases, malignancies (7/23), liver transplantation (7/23), and chronic renal diseases (3/23 chronic renal failure, 1/23 membranoproliferative glomerulonephritis, 1/23 lupus nephritis, 1/23 nephrotic syndrome), were most common (Table 1). Hypertension was the triggering factor in 78.2% of the cases, followed by immunosuppressive and antineoplastic agents (55.5%), liver transplantation (22.2%), and peritoneal dialysis (16.6%). Clinical signs suggesting the diagnosis of PRES: lethargy, confusion, coma, and encephalopathy were observed in all cases. Other clinical signs were seizures (95.6%), headache (60.8%), and visual impairment (21.7%). Seizure types were generalized (67.6%), partial (24.6%) or secondary generalized (7.8%).
| Case | Age/Sex | Underlying Disorder                      | Clinical presentation                  | Precipitating Factors                                      | Maximal BP (mm/Hg) | Antihypertensive agents |
|------|--------|-----------------------------------------|---------------------------------------|------------------------------------------------------------|-------------------|-------------------------|
| 1    | 4/M    | Acut liver failure, liver transplantation | Mental change, seizures               | Tacrolimus, liver transplantation                           | 100/60            | -                       |
| 2    | 9/M    | Wilson disease, liver transplantation    | Coma                                  | Cyclosporin, hypertension, liver transplantation            | 145/85            | Amlodipine              |
| 3    | 16/M   | Lymphoblastic lymphoma                   | Mental change, seizures, headache     | Vincristin, L-asparaginase                                  | 110/70            | -                       |
| 4    | 13/M   | Chronic renal failure                    | Mental change, seizures, headache     | Hypertension, Peritoneal dialysis                          | 165/105           | Captopril, peritoneal dialysis |
| 5    | 7/F    | Chronic renal failure                    | Mental change, seizures, headache, visual disturbance, papilloedema | Hypertension, Peritoneal dialysis                          | 150/100           | Enalapril, peritoneal dialysis |
| 6    | 13/M   | Membranoproliferative glomerulonephritis | Mental change, seizures, headache     | Hypertension                                               | 185/125           | Furosemide, nifedipine hemodialysis |
| 7    | 9/F    | WilmsTumor                               | Mental change, seizures, headache     | Vincristine                                                | 110/65            | -                       |
| 8    | 11/M   | Lupus Nephritis                          | Mental change, seizures, headache     | Cyclophosphamide, hypertension                             | 155/111           | Hemodialysis, enalapril, losartan, furosemide |
| 9    | 16/F   | Chronic liver failure, liver transplantation | Mental change, seizures              | Tacrolimus, liver transplantation, hypertension            | 135/95            | Amlodipine              |
| 10   | 10/F   | Acute lymphoblastic leukemia              | Mental change, seizures, headache, visual disturbance, papilloedema | Vincristine, L-asparaginase, Hypertension                  | 130/92            | Verapamil               |
| 11   | 9/F    | Chronic liver failure                    | Mental change, seizures, headache     | Hypertension                                               | 140/100           | Amlodipine, enalapril, furosemide |
|   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|
| 12 | 5/F | Chronic renal failure | Mental change, seizures, headache | Hypertension, Peritoneal dialysis, | 145/100 | Enalapril |
| 13 | 6/M | Lymphoblastic lymphoma | Mental change, seizures, headache | Hypertension | 160/121 | Amlodipine, enalapril, losartan |
| 14 | 9/F | Polyarteritis Nodosa | Mental change, seizures, headache | Hypertension | 155/106 | Verapamil |
| 15 | 7/M | Nephrotic Syndrome | Mental change, seizures, headache | Hypertension | 160/110 | Enalapril, losartan |
| 16 | 12/F | Wilson disease, liver transplantation | Mental change, seizures, visual disturbance | Tacrolimus, liver transplantation | 140/80 | Verapamil |
| 17 | 8/M | Chronic lymphoblastic leukemia | Mental change, seizures, visual disturbance, Mental change, seizures, visual disturbance, Mental change, seizures, headache | Vincristine, L-asparaginase | 140/87 | Verapamil |
| 18 | 6/M | Acute lymphoblastic leukemia | Mental change, seizures, visual disturbance, Mental change, seizures, visual disturbance, Mental change, seizures, headache | Vincristine, L-asparaginase | 130/90 | Ramipril |
| 19 | 10/M | Inflammatory bowel disease | Mental change, seizures, visual disturbance, Mental change, seizures, visual disturbance, Mental change, seizures, headache | Hypertension, total colectomy, tacrolimus | 185/110 | Ramipril, losartan |
| 20 | 1/M | Chronic liver failure, liver transplantation | Mental change, seizures | Tacrolimus, liver transplantation, Fludarabine, cytosine arabinoside, idarubicin | 180/100 | – |
| 21 | 3/F | Acute lymphoblastic leukemia | Mental change, seizures | Tacrolimus, liver transplantation, Fludarabine, cytosine arabinoside, idarubicin | 115/65 | Verapamil, ramipril, losartan |
| 22 | 2/F | Chronic liver failure, liver transplantation | Mental change, seizures, headache | Tacrolimus, liver transplantation, hypertension | 145/87 | – |
| 23 | 14/M | Chronic liver failure, liver transplantation | Mental change, seizures, headache | – | – | Verapamil |
Cranial imaging and EEG findings, clinical course, and antiepileptic drugs are summarized in Table 2. Cranial CT was performed in 16 patients: of these, four (25%) showed hypodense areas in posterior brain regions and hemispheres. Cranial MRI was performed at diagnosis in all, and on follow-up in 17 patients. Initial MRIs of all patients showed bilateral symmetric hyperintense lesions in occipital subcortical white matter on T2-weighted and FLAIR sequences, and hypointense lesions and vasogenic edema on T1-weighted images (Figures 1,2). In addition, frontal (13/23), parietal (12/23) and temporal (7/23) lobe involvements followed by cerebellum (6/23), basal ganglia (5/23), corpus callosum (7/23), brainstem (2/23), insular cortex (1/23), and thalamus (3/23) were observed. Lesions compatible with cytotoxic edema (11/23), contrast enhancement (1/23), and bleeding (3/23) were associated in certain cases (Table 2).

Figure 1: 16-year old girl after liver transplantation (patient 9). Axial MR images a. (T2-weighted) and b. and c. (fluid-attenuated inversion recovery) demonstrate edema in the occipital lobes and cerebellum. Diffusion-weighted images d. with b-1000 and e. with apparent diffusion coefficient (ADC) demonstrate increased diffusion in the occipital lobes. After 3 months of treatment, axial MR images f. and g. and ADC h. show normal findings.

Figure 2. 4-year old boy after liver transplantation (patient 1). Axial MR image a. (fluid attenuation inversion recovery) demonstrates involvement of bilateral globus pallidi and frontal and occipital lobes. Diffusion-weighted images b. with b-1000 and c. with apparent diffusion coefficient demonstrate decreased diffusion in the occipital lobes and globus pallidus.
| Case | Brain CT | Initial MRI findings | Atypical imaging | Follow up MRI (resolution/interval) | Intensive care Unit staying time (day) | Recovery time | EEG | Antiepileptic therapy | Prognosis            |
|------|----------|----------------------|------------------|-----------------------------------|---------------------------------------|---------------|-----|-----------------------|----------------------|
| 1    | None     | Prt, Occ             | Bg, Frt, cytotoxic edema, hemorrhage | Subtotal (18 thday) | 17 | 8 | None | None | None | Diplegic cerebral palsy |
| 2    | None     | Prt, Occ             | Frt, Cbl, hemor rhage, Bg, CC Bs, cytotoxic edema | None | 10 | - | None | None | None | Exitus |
| 3    | Cerebral atrophy | Tmp, Occ             | Frt, Cbl, CC | Total (1 month) | 2 | 1 | Normal | Levetiracetam | Exitus |
| 4    | Normal   | Prt, Occ             | Frt, cytotoxic edema | Subtotal (15 thday) | 7 | 3 | Voltage suppression, generalized epileptic abnormalities | Sodium Valproate | Recovery |
| 5    | Hypodensities, brainedema | Prt, Occ         | Frt, cytotoxic edema | None | 7 | 2 | Voltage suppression, generalized epileptic abnormalities | Sodium Valproate | Recovery |
| 6    | None     | Prt, Occ             | Frt, Cbl, cytotoxic edema | Subtotal (20 thday) | 10 | 2 | Normal | None | Recovery |
| 7    | Normal   | Tmp, Occ             | None | Total (2 month) | 2 | 2 | Voltage suppression, generalized epileptic abnormalities | Sodium Valproate | Recovery |
| 8    | None     | Tmp, Occ             | None | Subtotal (1 month) | 3 | 3 | Voltage suppression, generalized epileptic abnormalities | Sodium Valproate | Recovery |
| 9    | Cerebral atrophy | Prt, Occ             | Frt, Cbl, CC | Total (2 month) | 15 | 10 | Normal | Levetiracetam | Recovery |
| 10   | None     | Occ                  | Cytotoxic edema, Gd+ | Total (3 month) | 7 | 3 | Normal | Levetiracetam | Recovery |
| 11   | Cerebral atrophy | Tmp, Occ             | Frt, Cbl, Bg, Th | None | 25 | 7 | Normal | Levetiracetam | Follow-off |
| 12   | Hypodensities, brainedema | Tmp, Occ         | Frt | Total (3 month) | 13 | 5 | Normal | Sodium Valproate | Recovery |
| 13   | Lefoccipital meningeal thickening | Tmp, Cbl          | Frt | Total (1 month) | 2 | 2 | Normal | Levetiracetam | Exitus |
| 14   | None     | Occ                  | Frt | Total (20 thday) | 1 | 1 | Normal | Levetiracetam | Recovery |
| 15   | None     | Prt, Occ             | Frt | Subtotal (15 thday) | 2 | 2 | Voltage suppression | None | Recovery |
|   | Cerebral atrophy | Tmp, Occ | Frt, CC, insular cortex, cytotoxic edema | Subtotal (15th day) | 25 | 10 | Voltage suppression, Left sharp waves | Levetiracetam, Topiramate | Recovery |
|---|------------------|----------|--------------------------------------|---------------------|-----|----|--------------------------------------|--------------------------|----------|
| 16 | Cerebral atrophy | Prt, Occ | Th, CC, cytotoxic edema | Total (3 month) | 4  | 2  | Voltage suppression, Right sharp waves | Levetiracetam | Recovery |
| 17 | Cerebral atrophy | Occ      | None                                | Subtotal (20th day) | 15 | 3  | Normal                               | Levetiracetam | Recovery |
| 18 | Hypodensities, brain edema | Prt, Occ | Th, cytotoxic edema | Subtotal (15th day) | 35 | 5  | Voltage suppression, Left sharp waves | Sodium Valproate | Recovery |
| 19 | Normal           | Prt, Occ | Frt, Th, CC, cytotoxic edema | Subtotal (1 month) | 18 | 5  | None                                 | -                        | Recovery |
| 20 | Cerebral atrophy | Prt, Occ | None                                | None                | 3  | -  | None                                 | Phenytoin                | Exitus   |
| 21 | Hypodensities, brain edema | Prt, Occ | Bg, cytotoxic edema, hemorrhage | Subtotal (1 month) | 120 | 5  | Voltage suppression                  | Levetiracetam, Tetraplegia | Exitus   |
| 22 | Cerebral and cerebellar atrophy | Tmp, Occ | Frt, Bg, Bs, CC, cytotoxic edema | Subtotal (1 month) | 30 | 2  | Voltage suppression                  | Levetiracetam, Exitus    | Exitus   |

Abbreviations: Bg, basal ganglia; Bs, brainstem; Cbl, cerebellum; CC, corpus callosum; CT, computed tomography; EEG, electroencephalography; Frt, frontal; Gd+, gadolinium enhancement; Occ, occipital; Prt, parietal; Th, thalamus; Tmp, temporal
Patients stayed in the pediatric intensive care unit for mean 16.2 (1-120) days. The mean duration of acute encephalopathy was 3.6 (1-10) days. Hypertensive patients were treated with nifedipine, amlodipine, verapamil, captopril, enalapril, furosemide, or losartan. Potential causative drugs such as tacrolimus, cyclosporine, cyclophosphamide, cisplatin, vincristine, L-asparaginase were discontinued. Eighteen patients had a follow-up cranial MRI performed within 2-12 wk (mean 37.6 d) after the first one. Partial resolution of lesions was observed in MRIs performed within the first three weeks, and complete resolution, on those performed at 4 wk or later.

On long-term follow-up, one was lost to follow-up after discharge. Five patients died during the follow-up: the cause of death was neoplasm in three, and chronic liver disease with post-transplant complications in two. No patients died during the PRES episode. Overall, no correlation was detected between underlying disease and clinical or radiological findings.

Discussion
PRES may present with visual symptoms suggestive of posterior cerebral involvement, or with non-specific symptoms such as generalized or focal seizures, headache, nausea, vomiting, and mental changes. On the other hand, radiological findings are diagnostic. Morbidity and mortality in PRES may result from status epilepticus, intracranial hemorrhage or cerebral infarct (11,14,16,17). The pathophysiology of PRES is explained by two series of events initiated by hypertension: arterial spasm resulting in cytotoxic edema particularly in areas with limited arterial supply, and, more recently and more widely accepted, cerebral hyperperfusion and arterial hydrostatic edema followed by deterioration of cerebral autoregulation. In the 25% cases with normal blood pressure, the scenario is attributed to vasogenic edema due to various causes (8,11,18-20). On the other hand, the initiating role of hypertension can also be discussed, as hypertension can be secondary to acute encephalopathy and intracranial pressure. In our study, the predisposing factors were hypertension and antineoplastic or immunosuppressive medications. We had seven post-transplantation cases because our hospital is a transplantation referral center. The use of immunosuppressive agents after transplantation is a risk factor for PRES. It was detected in 4/40 patients with liver transplants (21). All our patients with organ transplantation had radiological findings other than typical posterior cerebral lesions. The presence of such radiological findings was not predictive of a specific course or outcome.

Our rate of atypical MRI findings, 82.6%, is higher than previously reported: 42.5% of 40 children and 43.8-58% in adult studies (22-25). Frontal lobe lesions were predominant. The susceptibility of the anterior cerebral regions to PRES as much as posterior ones may be related to the limitation of the anterior cerebral circulation in children, similar to the vertebro-basilar circulation (26). Because frontal involvement is frequent in any studies including those of the adult age group, the name of the syndrome as ‘posterior’ appears misleading. As previously reported, the extent of lesions were not correlated with the type and severity of clinical findings in our cases (4).

There is no specific recommendation for the need and timing for follow-up MRI, but imaging findings may persist along with triggering factors (16). Lesions had resolved only partially in our patients (n=9) who had their follow-up MRI within the first month, and completely in the others imaged later. The association of cytotoxic edema was reported with a worse neurological outcome (25). We had twelve cases with cytotoxic edema, of which eight recovered completely. Two patients had motor deficits due to concomitant intracranial hemorrhage.

Although this is not the largest series of pediatric PRES, its strengths lie in its single-center character, the inclusion of a considerable sub-series of transplant patients, the young age of patients (including two under 2 yr of age), and in particular, the uniform nature of imaging procedures, i.e., ADC mapping in all patients and evaluate by two neuroradiologists. Its limitations are the retrospective methodology and the different timing of follow-up images.

In conclusion, early imaging of at-risk patients for PRES, longitudinal and frequent imaging during and after the episode of PRES would be of importance to establish the hemodynamic changes taking part in the pathogenesis. However, the critical clinical condition of these patients often precludes such studies, and retro-
Clinical and Imaging Findings in Childhood Posterior Reversible Encephalopathy Syndrome

Prospective evaluations continue to contribute to the pool of knowledge in this disorder.

Author’s contribution
Güngör S: Designed the study, management of patient, conducted laboratory tests, analyzed the data and revision of manuscript
Selimoglu A: Revised and approved the manuscript for important intellectual content of the paper
Kılıç B: Diagnosis, management and writing the manuscript
Tabel Y: Management of patient, conducted laboratory tests
Ozgen U: Supervision of the work and revision of manuscript
Yılmaz S: Management of patient, conducted laboratory tests
Sığırcı A: Conducted laboratory tests and analyzed the data
All authors agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Conflict of interest
Authors declare they have no conflict of interest.

References
1. Hinchey J, Chaves C, Appignani B, et al. Reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334: 494-500.
2. Schwartz RB, Mulkern RV, Gudbjartsson H, Jolesz F. Diffusion weighted MR imaging in hypertensive encephalopathy: clues to pathogenesis. AJNR Am J Neuroradiol 1998;19: 859-62.
3. Pizon AF, Wolfson AB. Postpartum focal neurologic deficits: posterior leukoencephalopathy syndrome. J Emerg Med 2005;29: 163-6
4. Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc 2010;85: 427-32.
5. Nordby JA. Neurological presentation of poststreptococcal glomerulonephritis. Clin Pediatr (Phila) 1997;36: 105-8.
6. Wirrell EC, Hamiwka LD, Hamiwka LA, Grisaru S, Wei X. Acute glomerulonephritis presenting with PRES: a report of 4 cases. Can J Neurol Sci 2007;34: 316-21.
7. Benseler SM, Silverman ED. Neuropsychiatric involvement in pediatric systemic lupus erythematosus. Lupus 2007;16: 564-71.
8. Bartynski WS, Tan HP, Boardman JF, Shapiro R, Marsh JW. Posterior reversible encephalopathy syndrome after solid organ transplantation. AJNR Am J Neuroradiol 2008;29: 924-30.
9. Kitamura M, Furusu A, Hirose M, et al. A case of reversible posterior leukoencephalopathy syndrome in a patient on peritoneal dialysis. Clin Exp Nephrol 2010;14: 633–6.
10. Nakamura M, Fuchinoue S, Sato S, et al. Clinical and radiological features of two cases of tacrolimus-related posterior leukoencephalopathy in living related liver transplantation. Transplant Proc 1998;30: 1477-8.
11. Wu Q, Marescaux C, Wolff V, et al. Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation. Eur Neurol 2010;64: 169-77.
12. Tang JH, Tian JM, Sheng M, et al. Study of Posterior Reversible Encephalopathy Syndrome in Children With Acute Lymphoblastic Leukemia After Induction Chemotherapy. J Child Neurol 2016;31(3): 279-84.
13. Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol 2008;29: 1036-42.
14. Bartynski WS. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol 2008;29: 1043-9.
15. Children NHBPEPWGoHBPi, Adolescents. The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. Pediatrics 2004;114: 555-76.
16. Chou MC, Lai PH, Yeh LR, et al. Posterior reversible encephalopathy syndrome: magnetic resonance imaging and diffusion-weighted imaging in...
Clinical and Imaging Findings in Childhood Posterior Reversible Encephalopathy Syndrome

12 cases. Kaohsiung J Med Sci 2004;20: 381-8.
17. Pradhan A, Jairam A, Kumar RS, Srivastava A, Srivastava A, Sreevastava D, et al. Posterior reversible encephalopathy syndrome posttransplantation: a case report of possible association with cerebrospinal fluid leak after epidural catheterization. Transplant Proc 2009;41: 1957-60.
18. Bartynski WS, Boardman JF, Zeigler ZR, Shaddock RK, Lister J. Posterior reversible encephalopathy syndrome in infection, sepsis, and shock. AJNR Am J Neuroradiol 2006;27: 2179-90.
19. Won SC, Kwon SY, Han JW, Choi SY, Lyu CJ. Posterior reversible encephalopathy syndrome in childhood with hematologic/oncologic diseases. J Pediatr Hematol Oncol 2009;31: 505-8.
20. Hefzy HM, Bartynski WS, Boardman JF, Lacomis D. Hemorrhage in posterior reversible encephalopathy syndrome: imaging and clinical features. AJNR Am J Neuroradiol 2009;30: 1371-9.
21. Erol I, Alehan F, Ozcan F, Canan O, Haberal M. Neurological complications of liver transplantation in pediatric patients: A single center experience. Pediatr Transplant 2007;11: 152–9.
22. Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol 2008;65: 205-10.
23. Yoon SD, Cho BM, Oh SM, Park SH, Jang IB, Lee JY. Clinical and Radiological Spectrum of Posterior Reversible Encephalopathy Syndrome. J Cerebrovasc Endovasc Neurosurg 2013;15: 206-13.
24. Yamamoto H, Natsume J, Kidokoro H, et al. Clinical and neuroimaging findings in children with posterior reversible encephalopathy syndrome. Europ J Paediatr Neurol 2015;19: 672-8.
25. McKinney AM, Short J, Truwit CL, et al. Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. AJR Am J Roentgenol 2007;189: 904-12.
26. Chen TH, Lin WC, Tseng YH, Tseng CM, Chang TT, Lin TJ. Posterior Reversible Encephalopathy Syndrome in Children: Case Series and Systematic Review. J Child Neurol 2013;28: 1378-86.